Vir Biotechnology Inc. Announces COO Departure
On September 20, 2023, Vir Biotechnology Inc. (VIR) announced that Johanna Friedl-Naderer, the Company’s Executive Vice President and Chief Operating Officer, will be leaving the Company on...
Neutral
or
Vir Biotech News & Analysis
-
-
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14, down from $23. Analysts Geoff Meacham, Charlie Yang, Susan Chor, Hao Shen,...
-
BofA Securities Downgrades Vir Biotechnology to Neutral, 'Near-term data unlikely to lift sentiment'
(Updated - September 8, 2023 7:45 AM EDT) BofA Securities analyst lowered forecasts for HBV peak sales and extended potential launch timelines (YE2026e). To be clear, we aren't negative on...
-
H.C. Wainwright maintains Vir Biotech at 'buy' with a price target of $95.00
An analyst from H.C. Wainwright maintained Vir Biotech (NASDAQ: VIR) at 'buy' with a price target of $95.00 from a prior price target of %currency%%price%. Prior to this rating, Vir...
-
Vir Biotech earnings missed by $0.25, revenue fell short of estimates
Investing.com - Vir Biotech (NASDAQ: VIR) reported second quarter EPS of $-1.45, $0.25 worse than the analyst estimate of $-1.20. Revenue for the quarter came in at $3.8M versus the...
-
BofA Securities maintains Vir Biotech at 'buy' with a price target of $23.00
An analyst from BofA Securities maintained Vir Biotech (NASDAQ: VIR) at 'buy' with a price target of $23.00 from a prior price target of %currency%%price%. Prior to this rating, Vir...
-
JPMorgan maintains Vir Biotech at 'overweight' with a price target of $24.00
An analyst from JPMorgan maintained Vir Biotech (NASDAQ: VIR) at 'overweight' with a price target of $24.00 from a prior price target of %currency%%price%. Prior to this rating, Vir...
-
Goldman Sachs maintains Vir Biotech at 'buy' with a price target of $28.00
An analyst from Goldman Sachs maintained Vir Biotech (NASDAQ: VIR) at 'buy' with a price target of $28.00 from a prior price target of %currency%%price%. Prior to this rating, Vir Biotech...
-
Barclays maintains Vir Biotech at 'overweight' with a price target of $41.00
An analyst from Barclays maintained Vir Biotech (NASDAQ: VIR) at 'overweight' with a price target of $41.00 from a prior price target of %currency%%price%. Prior to this rating, Vir...
-
Morgan Stanley maintains Vir Biotech at 'equalweight' with a price target of $15.00
An analyst from Morgan Stanley maintained Vir Biotech (NASDAQ: VIR) at 'equalweight' with a price target of $15.00 from a prior price target of %currency%%price%. Prior to this rating, Vir...
-
Vir Biotechnology Inc. to Resume Trading at 8:30 a.m. After Phase 2 Study Fails
Vir Biotechnology Inc. (VIR) to Resume Trading at 8:30 a.m.Earlier: Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza...
-
Vir Biotechnology Inc. Announces Topline Data from Phase 2 PENINSULA Trial of VIR-2482
Vir Biotechnology, Inc. (Nasdaq: NASDAQ:VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic...
-
Vir Biotechnology Inc. Halted, News Pending
Vir Biotechnology Inc. (VIR) Halted, News Pending
-
Vir Biotech earnings missed by $0.19, revenue topped estimates
Investing.com - Vir Biotech (NASDAQ: VIR) reported first quarter EPS of $-1.06, $0.19 worse than the analyst estimate of $-0.87. Revenue for the quarter came in at $63M versus the consensus...
-
Vir Biotechnology Receives $10M Grant to Develop T Cell Vaccine Platform
Vir Biotechnology, Inc. (Nasdaq: NASDAQ:VIR) today announced that it received a new $10 million grant from the Bill & Melinda Gates Foundation to support Vir’s novel T cell vaccine...
-
Today's most important upgrades
By Davit Kirakosyan ACM Research, Inc. (NASDAQ:ACMR) shares jumped more than 11% intra-day today after Morgan Stanley upgraded the stock to Overweight from Underweight and raised its price...
-
Vir Biotechnology Inc. Misses Q4 EPS by 41c
Vir Biotechnology Inc . (NASDAQ:VIR) reported Q4 EPS of ($0.76), $0.41 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $49.4 million versus the consensus...
-
Vir Biotech earnings missed by $0.41, revenue fell short of estimates
Investing.com - Vir Biotech (NASDAQ: VIR) reported fourth quarter EPS of $-0.76, $0.41 worse than the analyst estimate of $-0.35. Revenue for the quarter came in at $49.4M versus the...
-
Vir Biotechnology Reports Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence
Vir Biotechnology, Inc. (Nasdaq: NASDAQ:VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final draft guidance recommending the...
-
Today's most important upgrades
By Davit Kirakosyan Goldman Sachs upgraded Vir Biotechnology (NASDAQ:VIR) to Buy from Neutral and raised its price target to $53.00 from $41.00, noting compelling risk/reward for an...
-
Vir Biotechnology risk/reward 'compelling' states Goldman Sachs
By Sam Boughedda Vir Biotechnology Inc.'s (NASDAQ:VIR) rating was lifted to Buy from Neutral, and its price target was raised to $53 from $41 at Goldman Sachs on Tuesday. Analysts there told...
-
Walmart, Home Depot and Credit Suisse fall premarket; General Mills rises
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, February 21st. Please refresh for updates. Walmart (NYSE:WMT) stock fell 3.9% after the retail giant forecast...
-
Vir Biotech earnings, Revenue beat in Q3
Investing.com - Vir Biotech reported on Thursday third quarter {{erl-1153039||earnings that beat analysts' forecasts and revenue that topped expectations. Vir Biotech announced earnings...
-
Vir Biotechnology Inc. Tops Q3 EPS by 172c
Vir Biotechnology Inc. (VIR) reported Q3 EPS of $1.30, $1.72 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $374.6 million versus the consensus estimate of...
-
Vir Biotechnology (VIR) Stock Sinks 11% as FDA Suspends the Use of Sotrovimab Against COVID-19
Vir Biotechnology, Inc. (NASDAQ:VIR) shares closed more than 11% lower today following the FDA's announcement that Sotrovimab is no longer authorized to treat COVID-19 in any U.S. state or...
-
Pre-Open Stock Movers 03/30: (ADGI) (VIR) (LULU) Higher; (CHWY) (MVST) (RH) Lower (more...)
Pre-Open Stock Movers:Adagio (ADGI) 50% HIGHER; ADG20 Met Primary Endpoints Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19Chewy (NYSE:CHWY) 14% LOWER; reported Q4...
-
Pre-Open Stock Movers 03/28: (KXIN) (HYMC) (TSLA) Higher; (BYND) (VIR) (MCHP) Lower (more...)
Pre-Open Stock Movers:Kaixin Auto Holdings (KXIN) 50% HIGHER; reached into a strategic partnership with Beijing Camping Club to order at least 20,000 new energy vehicles from Kaixin over the...
-
Wall Street Opens Lower as Fed Officials Keep Mood Cautious; Dow Down 240 Pts
By Geoffrey Smith Investing.com -- U.S. stock markets opened lower again on Tuesday as hawkish comments from Federal Reserve officials, together with increasing signs of a wave of...
-
Tesla, Vir Biotechnology, Illumina Rise Premarket; Rivian Falls
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, January 11th. Please refresh for updates. Tesla (NASDAQ:TSLA) stock rose 0.9% after the U.S. electric...
-
Vir Biotechnology Surges on Evidence Therapy Useful Against Omicron
By Dhirendra Tripathi Investing.com – Vir Biotechnology stock (NASDAQ:VIR) climbed 14% Wednesday after the company said it has more data showing that its Covid-19 antibody therapy is...
-
Eli Lilly, Ocugen, UPS Rise Premarket; Domino's Pizza Falls
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Wednesday, December 15th. Please refresh for updates. Eli Lilly (NYSE:LLY) stock rose 5.5% after the drug company...
-
Dollar Down, Aussie Up as Receding Omicron Fears Increases Risk Appetite
By Gina Lee Investing.com – The dollar was down on Wednesday morning in Asia, while the Australian dollar hit a one-week high. Investors’ risk appetite increased over indications that the...
-
How Nasdaq-Rally Led Nifty50 to Open in Green on Dec 8; Positive News on Omicron
By Malvika Gurung Investing.com -- Ahead of the Monetary Policy statement by the RBI Governor Shaktikanta Das, Dalal Street opened strong on Wednesday, with the Indian equity benchmarks BSE...
-
Oil Down, Assessment of Omicron’s Impact on Fuel Demand Continues
By Gina Lee Investing.com – Oil was down Wednesday morning in Asia, giving up gains from earlier in the week. Investors continue to assess the impact of the omicron COVID-19 variant on fuel...
-
Intel, Bumble, Palantir and MongoDB Rise Premarket
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, December 7th. Please refresh for updates. Intel (NASDAQ:INTC) stock rose 8.3% after the chip giant announced...
-
Omicron Fears Ease, Biden-Putin Summit, Intel Spin-Off - What's Moving Markets
By Geoffrey Smith Investing.com -- Risk-on sentiment returns to global markets as fears of Omicron-variant Covid-19 recede. U.S. stocks are set to open sharply higher again later, building...
-
Wall Street Opens Higher as Market Digests Omicron Risks; Dow up 390 Pts
By Geoffrey Smith Investing.com -- U.S. stock markets opened higher on Thursday, as investors tempered their concerns about the new Omicron strain of Covid-19 against the backdrop of...
-
Boeing, Snowflake, Five Below Rise Premarket; Apple Falls
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Thursday, December 2nd. Please refresh for updates. Apple (NASDAQ:AAPL) stock fell 2.8% after Bloomberg reported that...
-
Vaccine Stocks Benefit From Covid-19 Variant Concerns
By Sam Boughedda Investing.com — Covid-19 related vaccine stocks have made gains Friday after concerns were raised about a new coronavirus variant in South Africa that is said to have...
-
Vir Biotech Soars as Covid Therapy Found Effective at Cutting Deaths
By Dhirendra Tripathi Investing.com – Shares of Vir Biotechnology (NASDAQ:VIR) jumped 32% Thursday after the company said data showed its therapy, VIR-7831, had been found to be highly...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.39%
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Technology, Healthcare and Consumer Services sectors propelled shares lower. At the close in NYSE, the...
-
EXPLAINER-What are antibody therapies and who is developing them for COVID-19?
By Michael ErmanNEW YORK, June 9 (Reuters) - While some potential vaccines have emerged in the global race to find a way to stop the spread of COVID-19, many scientists and researchers...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.46%
Investing.com – U.S. equities were mixed at the close on Wednesday, as gains in the Technology, Healthcare and Telecoms sectors propelled shares higher while losses in the Oil & Gas,...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
